Clinical Trial Update: Melatonin on Clock Genes in Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating melatonin effects on clock genes in Parkinson's disease has been withdrawn after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Instituto Mexicano del Seguro Social | Conditions: Parkinson Disease | Phase 2, Phase 3 | Status: WITHDRAWN